Qisda Corp. (2352) has announced plans to acquire an additional 13.95% stake in Nobel, a prominent player in the medical retail channel, as part of its strategic effort to expand into the elderly care market. The acquisition will be conducted through a public tender offer at NT$175 per share, representing an 11.46% premium over Nobel’s closing price of NT$157 on the day of the announcement.
If the maximum acquisition target is met, Qisda will invest approximately NT$914 million (US$28.6 million), bringing its total ownership in Nobel to over 40%. While Qisda has not disclosed further details on its future plans for Nobel, it indicated the potential for incorporating the company into its consolidated statements.
Qisda Chairman Chen Qihong emphasized the importance of the medical sector in Qisda’s transformation strategy, particularly with the company’s growing focus on high-value businesses such as medical services, equipment, and pharmaceutical channels. The acquisition aligns with the company’s efforts to capitalize on the increasing demand for elderly care services, driven by an aging global population.
Nobel, best known for its “Dingding Pharmacy” brand, specializes in the sales of professional medicines, healthcare products, and medical beauty services. This acquisition will allow both companies to leverage complementary resources to expand their presence in the healthcare and pharmaceutical markets.
